Matthew K Szot sold $28k of CVKD
Chief Financial Officer at Cadrenal Therapeutics, Inc.. 2,000 shares at an average of $14.00, traded Aug 27, 2025, filed Aug 29, 2025.
Score components
- +22RoleCFO
- +5Trade size$28k at market
- 0Share of holdings soldSold 6.0% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +8.3%, 3m -27.6%, 6m -34.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001213900-25-082821, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 27, 2025 | SOpen-market sale Common Stock10b5-1 | -1,600 | $14.00 | $22k | 31,733 | Aug 29, 2025 |
| Aug 28, 2025 | SOpen-market sale Common Stock10b5-1 | -400 | $14.00 | $5,600 | 31,333 | Aug 29, 2025 |
Related signals
Other insiders at Cadrenal Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 5Weak | Cadrenal Therapeutics, Inc. | Quang X Pham Chairman and CEO | $22k 7,400 shares | -7% | |
| 11Weak | Cadrenal Therapeutics, Inc. | Quang X Pham Chairman, CEO and Interim CFO | $34k 11,156 shares | -10% | |
| 11Weak | Cadrenal Therapeutics, Inc. | Quang X Pham Chairman, CEO and Interim CFO | $40k 11,444 shares | -9% | |
| 5Weak | Cadrenal Therapeutics, Inc. | Quang X Pham Chairman, CEO and Interim CFO | $13k 4,126 shares | -3% | |
| 18Weak | Cadrenal Therapeutics, Inc. | Quang X Pham Chairman, CEO and Interim CFO | $70k 18,124 shares | -12% | |
| 20Weak | Cadrenal Therapeutics, Inc. | Quang X Pham Chairman, CEO and Interim CFO | $93k 22,385 shares | -13% | |
| 11Weak | Cadrenal Therapeutics, Inc. | Quang X Pham CEO and Chairman | $36k 8,285 shares | -5% | |
| 5Weak | Cadrenal Therapeutics, Inc. | Quang X Pham CEO and Chairman | $3,075 652 shares | -0% | |
| 13Weak | Cadrenal Therapeutics, Inc. | Quang X Pham CEO and Chairman | $69k 12,763 shares | -7% | |
| 5Weak | Cadrenal Therapeutics, Inc. | Quang X Pham CEO and Chairman | $6,629 1,165 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.